The leronlimab 350 mg dose versus placebo comparis

Quote:

---

The leronlimab 350 mg dose versus placebo comparison for the primary endpoint PDFF was statistically significant. Leronlimab compared to placebo also reached near significance for the secondary endpoint cT1.

---

So the results for 350mg (part 2, open-label are significant for primary (PDFF) and close for secondary.

This is good. What is needed is the topline report and the 700mg numbers of part one. My guess is that the CCR5 haplotype information is going to be brought to bear in order to understand the 700mg - 350mg differences (and 700 mg results).

Hopefully we will get the number soon to better understand.

In light of the humongous potential market for NASH any news can arguably be good news for the million of patients.

We need the top-line report !!! and ... go 700 mg , Go !!!